Datavault AI joins Wellgistics to launch $4B DelivMeds AI healthcare platform.
DelivMeds AI integrates blockchain, AI, and nationwide pharmacy infrastructure.
QOLPOM
IP enables wearables and drones for patient-specific drug delivery.
Tollo Health stake adds telemedicine, medical foods, and AI health coaching.
DelivMeds AI pilots in North Carolina, expanding digital healthcare nationwide.
Datavault AI (DVLT) traded at $0.4570, up 1.20%, after a volatile morning session. The company finalized a binding agreement with Wellgistics Health (NASDAQ:WGRX). The partnership aims to launch DelivMeds AI, combining blockchain, AI, and healthcare delivery.
The agreement covers three concurrent transactions valued at approximately $4 billion. Datavault AI expands its PharmacyChain license to include Healthcare-as-a-Service intellectual property. It also acquires QOLPOM IP and a controlling stake in Tollo Health, LLC.
DelivMeds AI will integrate EinsteinRx AI into blockchain-enabled smart contracts. The platform will improve prescription management, patient engagement, and last-mile drug delivery. National rollout begins in North Carolina in July 2026.
Datavault AI expanded PharmacyChain to cover Healthcare-as-a-Service technology. The license reaches over 6,500 pharmacies and 200 manufacturers nationwide. EinsteinRx AI manages eligibility verification, onboarding, and adherence support at scale.
The system also handles prior authorizations and cash-pay fulfillment efficiently. Blockchain smart contracts ensure secure, transparent processing of prescriptions. The platform supports AI-driven logistics and real-world asset tokenization.
The U.S. blockchain healthcare market was valued at $7.13 billion in 2023. It is projected to reach $595.31 billion by 2032 at a 63.5% CAGR. DelivMeds AI positions Datavault at the forefront of this rapid market expansion.
Datavault AI acquired QOLPOM IP from EOS Technology and Scilex Holdings. The portfolio enables wearables-driven biometric confirmation for patient-specific drug delivery. It includes Data Driven Drones for medical supply and sample collection.
The technology addresses compliance and fraud gaps in pharmaceutical distribution. It also improves last-mile delivery in rural and underserved markets. QOLPOM enhances the accuracy and safety of telehealth and pharmacy services.
Drone-enabled delivery of medical supplies is projected to grow from $430 million in 2023 to $2.49 billion by 2032. DelivMeds AI leverages this growth to scale patient access nationally.
Tollo Health adds clinical capabilities to DelivMeds AI through telemedicine and AI-enabled health coaching. It offers medical foods targeting weight-loss muscle loss, long COVID, and acute viral infections. The NFL Alumni Health partnership connects the platform directly to patients.
The acquisition strengthens DelivMeds’ consumer engagement and national brand presence. GLP-1 receptor agonist therapies, projected to grow from $66 billion in 2025 to $185 billion in 2033, form a key market. The platform integrates nutraceutical solutions with AI-driven behavioral health workflows.
The transactions remain subject to customary due diligence, board approvals, and execution of definitive agreements. DelivMeds AI combines blockchain infrastructure, AI technology and national pharmacy scale. The initiative represents a $4 billion effort to advance patient-centered healthcare delivery.
The post Datavault AI (DVLT) Stock: Partners With Wellgistics to Launch $4B DelivMeds AI appeared first on CoinCentral.
